Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Effect of SLCO1B1 Polymorphisms on High‐Dose Methotrexate Clearance in Children and Young Adults With Leukemia and Lymphoblastic Lymphoma

Clinical and Translational Science(2020)10.1111/cts.12879Source: DataRank Database

Effect of SLCO1B1 Polymorphisms on High‐Dose Methotrexate Clearance in Children and Young Adults With Leukemia and Lymphoblastic Lymphoma is a research paper published in Clinical and Translational Science (2020). On theSindex it has a DataRank of 0. It has been cited 44 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access44 citations

Download PDF

Cite:

Linked data & code

refsnp

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 4.28)OA: goldTopics (60)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Leena Choi ORCID,Nipun Utreja,Sara L. Van Driest ORCID,Christoph Stein ORCID,Richard Ho ORCID

Live enrichment

PubMed:32961024 PMC:PMC7877862 OpenAlex:https://openalex.org/W3088547182

NIGMS NIH HHS

Grant: R01 GM124109

NCI NIH HHS

Grant: K12 CA090625

NCATS NIH HHS

Grant: UL1 TR002243

NIGMS NIH HHS

Grant: R35 GM131770

NIGMS NIH HHS

Grant: R01 GM109145

FWCI

4.28

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1111/cts.12879

publisherhttps://doi.org/10.1111/cts.12879

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12879

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1111/cts.12879

publisherhttps://ascpt.onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12879

Fields of Study

Acute Lymphoblastic Leukemia researchChildhood Cancer Survivors' Quality of LifeDrug Transport and Resistance MechanismsAdolescentAdultAntimetabolites, AntineoplasticBody WeightChildChild, PreschoolDose-Response Relationship, DrugFemaleHumansInfantLeukemia, LymphoidLiver-Specific Organic Anion Transporter 1MaleMethotrexateModels, BiologicalPharmacogenomic TestingPharmacogenomic VariantsPolymorphism, Single NucleotidePrecursor Cell Lymphoblastic Leukemia-LymphomaYoung Adult

MeSH Terms

Pharmacogenomic VariantsPharmacogenomic TestingAdolescentAdultAntimetabolites, AntineoplasticBody WeightChildChild, PreschoolDose-Response Relationship, DrugFemaleHumansInfantLeukemia, LymphoidMaleMethotrexateModels, BiologicalPolymorphism, Single NucleotideLiver-Specific Organic Anion Transporter 1Precursor Cell Lymphoblastic Leukemia-LymphomaYoung Adult

Keywords

SLCO1B1MethotrexateMedicinePharmacogeneticsDosingPharmacokineticsPharmacologyTherapeutic drug monitoringOncologyInternal medicineLymphoblastic LeukemiaDrugGenotypeLeukemiaBiologyGeneticsGene

Sustainable Development Goals

SDG 0: Good health and well-being